Business Wire

Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021

Share

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from the clinical development program for RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent Clostridioides difficile (C. difficile) infection, as part of IDWeek 2021. The congress will take place virtually from September 29 – October 3, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005220/en/

Notably, the data include the first-time presentation of an analysis from five prospective clinical studies, which represent the totality of this comprehensive body of clinical evidence for a microbiota-based live biotherapeutic. IDWeek acknowledged this presentation and its author, Lindy L. Bancke, PharmD, Head of Clinical Development at Rebiotix, as one of only four recipients of the 2021 Program Committee Choice award, based on outstanding scientific research.

Additionally, the company will present data demonstrating the association of RBX2660 in gut microbiome restoration and the impact of the decolonization of deadly multi-drug resistant organisms.

“Our data presentations at IDWeek will not only add to the growing body of clinical evidence supporting RBX2660, but they bring together nearly a decade of research that show exciting advancements in how RBX2660 clinical outcomes relate to microbiome composition,” said James P Tursi, M.D., Chief Scientific Officer, Ferring Pharmaceuticals U.S.

The clinical development program for RBX2660 is the largest and most robust ever conducted in the field of microbiome-based therapeutics for recurrent C. diff infection, enrolling more than 1,000 patients to date and including two studies that followed patients for 24 months.

The details of the five abstracts being presented are as follows:

Presentation Title: Efficacy of lnvestigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioidesdifficile Infection: Data from Five Prospective Clinical Studies
Presenting Author: Lindy Bancke, PharmD, Head of Clinical Development, Rebiotix
EMBARGOED UNTIL: Wednesday, September 29 at 8:00 AM EDT

Presentation Title: Antimicrobial Resistance Genes were Reduced Following Administration of Investigational Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
Presenting Author: Heidi Hau, PhD, Director of Translational Biology, Rebiotix
EMBARGOED UNTIL: Wednesday, September 29 at 8:00 AM EDT

Presentation Title: Treatment Success in Reducing Recurrent Clostridioides difficile Infection with lnvestigational Live Biotherapeutic RBX2660 is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
Presenting Author: Ken Blount, PhD, Chief Scientific Officer, Rebiotix and VP Microbiome Research, Ferring Pharmaceuticals
EMBARGOED UNTIL: Wednesday, September 29 at 8:00 AM EDT

Presentation Title: Safety of lnvestigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data From Five Prospective Clinical Studies
Presenting Author: Tricia Braun, PharmD, Associate Director of Clinical Research, Rebiotix
EMBARGOED UNTIL: Wednesday, September 29 at 8:00 AM EDT

Presentation Title: Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection-Results from the PUNCH CD3 Phase 3 Trial
Presenting Author: Romeo Papazyan, PhD, Scientist, Ferring Research Institute
EMBARGOED UNTIL: Wednesday, September 29 at 8:00 AM EDT

IDWeek has made abstracts available on their website.

About the gut microbiome and C. difficile infection

C. difficile infection (CDI) is a serious and potentially deadly disease that impacts people across the globe. The C. difficile bacterium causes debilitating symptoms such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea and colitis (an inflammation of the colon).1 Declared a public health threat by the U.S. Centers for Disease Control and Prevention (CDC) requiring urgent and immediate action, CDI causes an estimated half a million illnesses and tens of thousands of deaths in the U.S. alone each year.1,2,3

C. difficile infection often is the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system.4,5 Up to 35% of CDI cases recur after initial diagnosis6,7 and people who have had a recurrence are at significantly higher risk of further infections.8,9,10,11 After the first recurrence, it has been estimated that up to 60% of patients may develop a subsequent recurrence.12

Recurrent C. difficile infection (rCDI) is associated with disruptions to the gut microbiome, or “dysbiosis”. The gut microbiome is a highly-diverse microbial community that plays an essential role in human health. There is a growing body of evidence that shows when there is a disruption of the composition and/or diversity of the gut microbiome, there may be an associated risk for serious illnesses, including CDI. The current standard of care treatment for rCDI is antibiotics, which does not address the underlying dysbiosis or restore the gut microbiome.13 The use of antibiotics has been shown to disrupt the ecology of the gut microbiome and are a predominant risk factor for rCDI.6,7,13

Restoring the gut microbiome is increasingly accepted as a promising treatment option for recurrent C. difficile infection.14

About RBX2660

RBX2660 is a potential first-in-class microbiota-based live biotherapeutic being studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome data collected over six controlled clinical trials with more than 1,000 participants.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. The Ferring Research Institute Inc. (FRI), based in San Diego, USA, is part of the Global Drug Discovery & External Innovation unit, which is the research and ideas engine of Ferring Pharmaceuticals. FRI is an integral part of Ferring’s R&D organization, focusing on early drug discovery and development. Connect with us on our dedicated microbiome therapeutics development channels on Twitter and LinkedIn.

About Rebiotix

Rebiotix Inc, a Ferring Company, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix has a diverse pipeline of investigational drug products built on its pioneering microbiota-based MRTTM drug platform. The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com, or connect with us on Twitter, Facebook, LinkedIn and YouTube.

About IDWeek

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). More information can be found at www.idweek.org.

References:

  1. Centers for Disease Control and Prevention. What Is C. Diff? 17 Dec. 2018. Available at: https://www.cdc.gov/cdiff/what-is.html.
  2. Centers for Disease Control and Prevention. Biggest Threats and Data, 14 Nov. 2019. Available at: https://www.cdc.gov/drugresistance/biggest-threats.html.
  3. Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile. Clin Microbiol Infect. 2012;18(suppl 6):2-4.
  4. Centers for Disease Control and Prevention. 24 June 2020. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf.
  5. Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609.
  6. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834.
  7. Cornely OA, et al. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin. Clinical Infectious Diseases. 2012;55(S2):S154–61.
  8. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009;23(3):727-743.
  9. Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims. J Manag Care Spec Pharm. Published online March 11, 2021.
  10. Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012; 18 (Suppl. 6): 21–27.
  11. Smits WK, et al. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. doi: 10.1038/nrdp.2016.20.
  12. Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm. 2013;66(6):361-368.
  13. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39.
  14. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415. 

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Levis Guzzi
Director, Brand Communications
P: +18622865254
E: Heather.Guzzi@ferring.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

China is Flying High Again: Cirium Survey Shows Remarkable Consumer Confidence for a Travel Restart21.10.2021 04:00:00 CEST | Press release

Chinese travelers are leading the airline travel recovery, with 96% intending to travel, according to a new survey by Cirium, the aviation analytics company. 81% of respondents say they plan to fly at least once within the next 12 months and 50% plan to fly by this autumn. Of those planning to travel, 73% stated it was for leisure with only 24% planning business travel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005941/en/ Cirium's new Traveler Intelligence Report reveals China is flying high again. (Graphic: Business Wire) The pent-up demand is also reflected in China’s passenger traffic, which is showing signs of a strong recovery. As of September 2021, China traffic was at 87% of 2019 levels — way ahead the rest of Asia (42%). The survey revealed that two thirds (66%) of Chinese travelers have taken a domestic flight since the start of the pandemic. Cirium schedules data reveal domestic travel in Q4 is primed to

Ricardo Wins Riyadh Air Quality Contract21.10.2021 01:01:00 CEST | Press release

World-class environmental, engineering and strategic consulting company Ricardo will be continuing to provide key air quality monitoring and data analysis in the Middle East with a new three-year agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005973/en/ Ricardo signs Riyadh Air Quality Contract (Photo: Business Wire) Working in collaboration with air monitoring equipment supplier, Envirozone LLC, Ricardo will quality assure, audit and ratify data from a world class monitoring network in Saudi Arabia’s capital for the Royal Commission for Riyadh City (RCRC). Ricardo’s Air Quality and Environment Practice Director, Sean Christiansen said: “This new contract cements Ricardo’s business in Saudi Arabia; continuing to work with Envirozone LLC on behalf of the Royal Commission for Riyadh City, our teams of experts will be delivering a leading edge, sustainable solution in support of the city’s ambitions for continu

Conviva Announces Streaming Platform Expansion Solving Audience Measurement Challenges Globally20.10.2021 20:00:00 CEST | Press release

Conviva, the continuous measurement platform for streaming media, today announces the availability of its technology and real-time data to enable end-to-end advertising audience measurement for its publisher customers and their ecosystem partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005928/en/ Conviva's streaming platform expansion delivers purpose-built technology and real-time data to enable end-to-end advertising audience measurement for publisher customers and their ecosystem partners. (Grapic: Business Wire) Conviva’s global streaming audience measurement technology promises to deliver unique, innovative, and industry-changing solutions based on: Session-level and census-level measurement Antiquated third-party web technologies like beacons, logs, pixels or outdated and inaccurate panel methodologies are incapable of dealing with today’s complex device fragmentation. Conviva’s Stream Sensor™ provides co

Developing Telecoms: A Green Road to a Greener Future: MTN at BWS 202120.10.2021 18:00:00 CEST | Press release

Developing Telecoms reported that lowering carbon emissions has become an increasing priority for the largest players in the telecoms sector due to the role that ICT can play in helping other industries decarbonizes. At the Better World Summit for Green ICT held at Huawei’s Innovation Lab in Dubai, various speakers explored how the ICT industry will be able to facilitate a greener society – and why this was particularly important in emerging markets regions, including Africa. MTN Group executive, Chief Procurement Officer Dirk Karl took the stage to discuss how operators had a role to play in emerging markets. Karl described this beyond simply the purpose of business – operators have responsibility to enable everyone the benefits of a modern, connected life, and MTN is still deploying and densifying networks in Africa. “Our work is not just about flourishing the business – it has a purpose, and this was proven under COVID, of being system-relevant to our wider economies in order to con

Verimatrix Announces Third Quarter 2021 Revenue20.10.2021 17:45:00 CEST | Press release

Regulatory News: Verimatrix (Paris:VMX) today announced its revenue for the third quarter ended September 30, 2021. Amedeo D’Angelo, Chairman and CEO, commented: “During the third quarter, we executed the implementation of our accelerated shift toward a subscription-based business, including through SaaS offerings. It included further developing the go-to-market strategy as well as reviewing organization and expenses to ensure we are spending and investing in alignment with our strategy. At the same time, we continue to expand our cloud-based offerings, as illustrated with the release of the Verimatrix Multi-DRM Core service earlier in 2021. Verimatrix is experiencing continuous growth of its SaaS business, as illustrated with the sequential growth of the ARR, even though products and offerings have not yet been changed to be subscription-only and “cloud first.” This growth should be further supported by new SaaS products going live throughout 2022. Additionally, the shift in our contr

NetApp Simplifies and Speeds Digital Transformation for Customers Through Deep, Industry-Leading Public Cloud Relationships20.10.2021 17:00:00 CEST | Press release

NetApp (NASDAQ: NTAP) a global, cloud-led, data-centric software company, today announced continued growth and momentum helping organizations unlock the best of cloud at less cost, through its collaboration with the world’s three largest public clouds. NetApp’s expansion in the cloud has been driven by customers and supported by these partnerships, accelerating NetApp’s public cloud services’ customer and financial growth by bringing its leading CloudOps and ITOps solutions to existing and new addressable customers. Furthering its investment in the cloud, NetApp acquired Data Mechanics in early fiscal year (FY)’22, and this month announced the intent to acquire CloudCheckr to bolster the Spot by NetApp portfolio’s existing continuous cloud optimization capabilities. This growth, driven by NetApp’s ONTAP data management software, which provides high-performance shared storage for file and block workloads, has propelled the native integration of NetApp’s cloud file services into each of

NetApp Expands Hybrid Cloud Solutions Portfolio to Unlock Best of Cloud20.10.2021 17:00:00 CEST | Press release

Today at INSIGHT 2021, NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, announced new additions and enhanced capabilities across its hybrid cloud portfolio to help organizations modernize their IT infrastructures and accelerate digital transformation. Delivering new secure ways to consume and operate data services on-premises and in the cloud, NetApp hybrid cloud solutions make it simpler for enterprise customers to put their data to work — wherever and whenever they need it. As the only solutions provider with native integrations for the world’s largest public clouds, NetApp’s industry leading ONTAP® software continues to serve as the foundation for hybrid cloud. With the latest release of ONTAP, NetApp is introducing enhanced protection against ransomware, expanded data management capabilities, and NVMe/TCP support for accelerated performance. The company is also announcing new digital wallet capabilities for NetApp Cloud Manager and enhanced data services f